Mustang Bio
MA - WorcesterBiotechnology
Focus: Mustang Bio is an early-stage immunotherapy biotech focused on CAR-T cell therapies for hematologic malignancies and oncology. The company operates as a pre-revenue biotech with a lean pipeline in early clinical stages.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Mustang Bio
AI assessmentNot HiringNo open roles listed right now. Follow Mustang Bio to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
5 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Prior MB-102 CAR-T cell investigational product.
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Clinical Trials (1)
NCT05645744Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
N/AHelp build intelligence for Mustang Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.